Pfizer Tests COVID-19 Vaccine in Children Under 12
Pfizer is evaluating its COVID-19 vaccine in children under 12, enrolling up to 4,500 youngsters in a clinical trial across more than 90 sites in the U.S. and beyond.
The phase 2/3 study has already begun for participants aged 5 to 11 and it will start in the coming weeks for younger participants. The trial will assess a 3 mcg dose in children aged 6 months to 5 years and a 10 mcg dose for those aged 5 to 11 years.
The vaccine has already been cleared for use in children as young as 12 in the U.S. and EU. The approved dose for adolescents and adults is 30 mcg.